- Home
- CBAN vs ANNX Comparison
CBAN vs ANNX Comparison
Compare CBAN & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- ANNX
- Stock Information
- Founded
- CBAN 1975
- ANNX 2011
- Country
- CBAN United States
- ANNX United States
- Employees
- CBAN N/A
- ANNX N/A
- Industry
- CBAN Major Banks
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- CBAN Finance
- ANNX Health Care
- Exchange
- CBAN Nasdaq
- ANNX Nasdaq
- Market Cap
- CBAN 287.3M
- ANNX 252.3M
- IPO Year
- CBAN 1998
- ANNX 2020
- Fundamental
- Price
- CBAN $17.44
- ANNX $3.01
- Analyst Decision
- CBAN
- ANNX Strong Buy
- Analyst Count
- CBAN 0
- ANNX 4
- Target Price
- CBAN N/A
- ANNX $12.50
- AVG Volume (30 Days)
- CBAN 50.8K
- ANNX 1.5M
- Earning Date
- CBAN 07-23-2025
- ANNX 08-11-2025
- Dividend Yield
- CBAN 2.64%
- ANNX N/A
- EPS Growth
- CBAN 14.66
- ANNX N/A
- EPS
- CBAN 1.43
- ANNX N/A
- Revenue
- CBAN $113,756,000.00
- ANNX N/A
- Revenue This Year
- CBAN $18.25
- ANNX N/A
- Revenue Next Year
- CBAN $7.59
- ANNX N/A
- P/E Ratio
- CBAN $12.17
- ANNX N/A
- Revenue Growth
- CBAN 3.33
- ANNX N/A
- 52 Week Low
- CBAN $11.93
- ANNX $1.29
- 52 Week High
- CBAN $18.49
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- CBAN 68.69
- ANNX 69.08
- Support Level
- CBAN $16.45
- ANNX $2.30
- Resistance Level
- CBAN $17.38
- ANNX $2.98
- Average True Range (ATR)
- CBAN 0.40
- ANNX 0.18
- MACD
- CBAN 0.18
- ANNX 0.02
- Stochastic Oscillator
- CBAN 89.92
- ANNX 80.14
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.